Open AccessHUBUNGAN GENOTIPE rs 1042713 (Arg16Gly) DENGAN EFEKTIVITAS 2-AGONIS PADA PENDERITA ASMA
Author(s) -
Sri Haryanti,
Zullies Ikawati,
Mustofa Mustofa,
Tri Murti Andayani
Publication year - 2021
Publication title -
jurnal ilmu farmasi dan farmasi klinik/jurnal ilmu farmasi and farmasi klinik
Language(s) - English
Resource type - Journals
eISSN - 2716-3814
pISSN - 1693-7899
DOI - 10.31942/jiffk.v18i01.4894
Subject(s) - genotype , agonist , asthma , pharmacogenomics , medicine , biology , genetics , gene , receptor
To produce an effect, the agonist drug 2 will bind to the ADRB2 receptor. The effect of agonist 2
shows variation between individuals due to the presence of encoding gene polymorphisms. There are
80 ADRB2 polymorphisms, including Arg16Gly in amino acids 16. The innate ADRB2 genotype is
called wildtype, whereas mutated ones is called mutant. The purpose of this study was to determine
whether there was a relationship between genotype rs 1042713 (Arg16Gly) and the effectiveness of
β2-agonist drugs in asthma sufferers. This study was an observational study with a cross sectional
design and prospective data collection. Examination of the presence of gene polymorphisms and
assessment of effe A total of 101 asthma patients who met the inclusion criteria were sorted by
genome type by pharmacogenomic examination uses the Asthma Control Test (ACT) questionnaire.
The results of the statistical test with chi square to determine the relationship of genome type and
asthma control obtained p value 0.131. The comparison of the effectiveness of the wildtype genome
is more effective than the mutant of 1.887x, and heterozygote is more effective 1,667x greater than
the mutant. There is no significant relation between genotypes rs 1042713 (Arg16Gly) with
effectiveness, but the possibility of clinical effectiveness is different.
Keywords: Asthma, β2-agonist, ADRB2, genotype, effectiveness.